Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIGHSOX: Trastuzumab with S-1 plus oxaliplatin for HER2-positive advanced gastric cancer
jRCTs051180196Phase 2Completed
- Sponsor
- The Cancer Collective
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, tegafur and oxaliplatin in gastric adenocarcinoma, sponsored by The Cancer Collective. Primary endpoint: Response rate. Started Jun 2015; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on jRCTs051180196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180196.